Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Most investors view artificial intelligence (AI) as a battle between Nvidia, OpenAI, and other technology giants. But a new bottleneck is emerging that could shape the industry's future.
So many stocks have swelled in value thanks to the artificial intelligence boom.
The auto parts retailer is facing slowing growth and challenges with international expansion.
Yext's fiscal Q1 report arrived with better-than-expected earnings, but investors are focusing on other aspects of the business update.
AST SpaceMobile, Intuitive Machines, and Rocket Lab are among the most promising space stocks right now.
Just because a stock is the obvious choice doesn't mean it's wrong.
With the right strategy, you have a better chance of keeping up.
Micron is slated to report fiscal third-quarter earnings later this month.
From University Lab to Quantum Hype Stock IonQ (NYSE:IONQ) hit the public market in October 2021 via a SPAC merger with dMY Technology Group III, becoming the first pure-play quantum computing stock investors could actually buy. The pitch was bold: a trapped-ion architecture spun out of University of Maryland and Duke research, aimed at solving ... What a $1,000 Bet on IonQ Since Its SPAC Debut Is Worth Today
The stock is down 20% so far this year.
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was “Welcome back, my friends to the show that never ends.” On cue, the never-say-die stock market shook off early worries and all the major indices closed higher on Tuesday. Like the proverbial broken record, the S&P 500 ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Bra
The crypto market is struggling this year. But it could bounce back.
The semiconductor manufacturer is up almost 500% in the last twelve months.
At $244.58, Oracle (NYSE:ORCL) is drawing fresh investor scrutiny. The database giant just printed a quarter that reframes its entire investment narrative, turning a sleepy enterprise software story into one of the most aggressive AI infrastructure plays in mega-cap tech. Oracle sells database software, enterprise applications like NetSuite and Fusion ERP, and increasingly the cloud ... Buy, Hold, or Sell: Is Oracle Stock a Buy at $245?
The bears have been quiet in the last two years, even though the market is much more frothy by their standards. And at this point, who would want the permabear tag while the rest of the market keeps on climbing ad infinitum? Andrew Ross Sorkin seems to be the person. His arguments are worth lending ... CNBC Anchor Issues Dire Stock Market Warning: “I Can Assure You… We Will Have a Crash”
Its revolutionary CASGEVY treatment could be a sign of what's to come.
Uh-oh. Looks like Intuitive Machines needs to raise cash again.
From SpaceX to Anthropic, the pipeline of blockbuster initial public offerings is moving fast. The Honeywell -backed upstart is slated to go public on Thursday, according to Nasdaq, meaning the IPO likely will be priced later Wednesday.
Cognyte beat Wall Street's sales estimate for last quarter, but there was a big catch.
Yes, Red Cat just won an Army contract. But how much is it worth?
Is it the right time to increase your exposure to gold?
Small-cap dividend investing has a credibility problem, and the Invesco S&P SmallCap High Dividend Low Volatility ETF (NYSEARCA:XSHD) is built to solve it. XSHD screens the S&P SmallCap 600 for the highest yielders with the lowest realized volatility, on the theory that small companies can pay real income without the share-price whiplash investors usually accept. ... Real Dividend Growth Exists in Small Caps, Just Not Where You’d Expect
Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world’s best-selling medicine, threw off the cash that funded everything else. Bears had been warning about its U.S. patent cliff for years, and when biosimilars finally hit in 2023, the drug went into freefall. Humira sales dropped to just $688 million in Q1 2026, ... AbbVie Delivers 400% Returns Beating The S&P 500 by 139%
Its current yield won't wow investors, but that isn't what ultimately matters.
High-bandwidth memory chips are hardware that’s essential for AI — and their makers can’t keep up with demand
Booming AI infrastructure spending has sent Bloom Energy soaring. Could Plug Power be the next beneficiary?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
